Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Procter & Gamble Co.

www.pg.com

Latest From Procter & Gamble Co.

Innovating Outside OTC Monograph Lines: Trending Acne Patches, Hand And Foot Antiperspirants

Industry and the FDA agree that the OTC drug monograph system is direly in need of reform, but innovating with noncompliant dosage forms and indications, without approved new drug applications, is a risk companies need to weigh seriously, says Arnall Golden Gregory partner Alan Minsk. The FDA offers perspective on its OTC monographs for acne and antiperspirant products.

United States Regulation

Pepto-Bismol Ultra Works As Name But Not For P&G To Claim Twice Original Product's Strength

To understand how Pepto-Bismol Ultra could be considered twice as strong as original as stated on packaging, consumers would need to "carefully review the Drug Facts on the back of both" products and "recognize that the active ingredient in both products is 525 mg of bismuth subsalicylate" but Ultra's dose is half original's.

OTC Drugs Commercial

Health And Wellness Executive Decisions: CHPA Counsel, CRN SVP, Gellar For Colgate

CHPA appoints Anne Marie Murphy deputy general counsel; CRN promotes Andrew Wong to senior VP, scientific and regulatory affairs; and Sarah Michelle Gellar promotes the Colgate Optic White High Impact line.

Appointments Commercial

CIR Experts Close Book (For Now) On Parabens: Safe Individually Or At Sum Concentration Of ≤0.8%

NGO Women’s Voices for the Earth supports the 0.8% limit on total parabens content adopted by the Cosmetic Ingredient Review Expert Panel at its 16-17 September meeting. WVE remains concerned, however, about certain assumptions made by the panel in the lengthy re-review process that led to its final amended report.

Beauty Cosmetic Ingredients
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register